
-
Ukraine's chief rabbi sings plea to Trump to side with Kyiv
-
Australian mushroom meal victim 'hunched' in pain, court hears
-
Lakers dumped out of playoffs by Wolves, Rockets rout Warriors
-
Booming tourism and climate change threaten Albania's coast
-
US reaching out to China for tariff talks: Beijing state media
-
Tariffs prompt Bank of Japan to lower growth forecasts
-
Kiss faces little time to set Wallabies on path to home World Cup glory
-
Serbian students, unions join forces for anti-corruption protest
-
Slow and easily beaten -- Messi's Miami project risks global embarrassment
-
Fan in hospital after falling to field at Pirates game
-
Nuclear power sparks Australian election battle
-
Tokyo stocks rise as BoJ holds rates steady
-
Bank of Japan holds rates, lowers growth forecasts
-
'Sleeping giants' Bordeaux-Begles awaken before Champions Cup semis
-
Napoli eye Scudetto as Inter hope for post-Barca bounce-back
-
Germany's 'absolutely insane' second tier rivalling Europe's best
-
PSG minds on Arsenal return as French clubs scrap for Champions League places
-
UK WWII veteran remembers joy of war's end, 80 years on
-
Myanmar junta lets post-quake truce expire
-
Rockets romp past Warriors to extend NBA playoff series
-
Messi, Inter Miami CONCACAF Cup dream over as Vancouver advance
-
UN body warns over Trump's deep-sea mining order
-
UK local elections test big two parties
-
US judge says Apple defied order in App Store case
-
Seventeen years later, Brood XIV cicadas emerge in US
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
Australian guard Daniels of Hawks named NBA's most improved
-
Mexico City to host F1 races until 2028
-
Morales vows no surrender in bid to reclaim Bolivian presidency
-
Ukraine, US sign minerals deal, tying Trump to Kyiv
-
Phenomenons like Yamal born every 50 years: Inter's Inzaghi
-
Ukraine, US say minerals deal ready as Kyiv hails sharing
-
Global stocks mostly rise following mixed economic data
-
O'Sullivan says he must play better to win eighth snooker world title after seeing off Si Jiahui
-
Sabalenka eases past Kostyuk into Madrid Open semis
-
Netflix's 'The Eternaut' echoes fight against tyranny: actor Ricardo Darin
-
US economy unexpectedly shrinks, Trump blames Biden
-
Barca fight back against Inter in sensational semi-final draw
-
Meta quarterly profit climbs despite big cloud spending
-
US Supreme Court weighs public funding of religious charter school
-
Climate change made fire conditions twice as likely in South Korea blazes: study
-
Amorim says not even Europa League glory can save Man Utd's season
-
Syria reports Israeli strikes as clashes with Druze spread
-
Ukraine, US say minerals deal ready as suspense lingers
-
Everything is fine: Trump's cabinet shrugs off shrinking economy
-
Chelsea boss Maresca adamant money no guarantee of success
-
Wood warns England cricketers against 'dumb' public comments
-
US economy shrinks, Trump blames Biden

Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
A.Ruegg--VB